

Contents

Contributors	xi
Preface	xiii
1 Similarities and differences in the pathophysiology of asthma and COPD	1
<i>J. Christian Virchow</i>	
1.1 Introduction	1
1.2 Pulmonary function abnormalities in asthma and COPD	3
1.3 Risk factors for asthma and COPD	5
1.4 Cellular inflammation in asthma and COPD	8
1.5 Distribution and consequences of inflammation in asthma and COPD	9
1.6 Patterns of epithelial injury in asthma and COPD	10
1.7 Airway hyperresponsiveness	10
1.8 Beta-receptor blockers	10
1.9 Differential diagnosis of asthma and COPD	11
1.10 Overlap syndrome	12
1.11 Conclusion	12
References	13
2 Glucocorticoids: pharmacology and mechanisms	16
<i>Peter J. Barnes</i>	
2.1 Introduction	16
2.2 Chemical structures	16
2.3 The molecular basis of inflammation	17
2.4 Cellular effects of glucocorticoids	19
2.5 Glucocorticoid receptors	20
2.6 Glucocorticoid activation of gene transcription	22
2.7 Suppression of inflammatory genes	23
2.8 Steroid resistance	29
2.9 Interaction with β_2 -adrenergic receptors	32
2.10 Conclusions	33
References	33
3 Inhaled corticosteroids: clinical effects in asthma and COPD	38
<i>Paul M. O'Byrne and Desmond M. Murphy</i>	
3.1 Introduction	38
3.2 Anti-inflammatory activity of corticosteroids	38
3.3 Routes of administration	39

3.4	Absorption and fate of corticosteroids	41
3.5	Currently available inhaled corticosteroids	41
3.6	Efficacy in asthma	43
3.7	Efficacy in COPD	44
3.8	Side effects of ICS	46
3.9	Conclusions	49
	References	49
4	LABAs: pharmacology, mechanisms and interaction with anti-inflammatory treatments	53
	<i>Gary P. Anderson</i>	
4.1	Galenic forms of LABAs: formulations, isomers, enantiomers, diastereomers and salts	55
4.2	Absolute and functional β_2 -adrenoceptor selectivity	56
4.3	Cellular organization of receptor clusters: functional structure of the β_2 -adrenoceptor and mode of signalling	58
4.4	Dimers and oligomers: homo- and heterodimerism/oligoism	60
4.5	Pharmacogenomics of the β_2 -adrenoceptor and adenylylate cyclase polymorphism in relation to LABAs	61
4.6	Understanding the 'reassertion' paradox, 'exosites' and relative speed of onset: the membrane diffusion microkinetic model of LABA action	61
4.7	Regulation and desensitization	63
4.8	Full versus partial agonism (pharmacological efficacy)	64
4.9	Beta-blockers not LABAs?	67
4.10	Non-receptor-mediated effects?	68
4.11	Biochemical basis of functional antagonism and its critical role in LABA action in disease and exacerbations	68
4.12	Molecular cooperativity between LABAs and steroids	69
4.13	Perspective	73
	References	73
5	Long- and ultra-long-acting β_2-agonists	81
	<i>Mario Cazzola and Maria Gabriella Matera</i>	
5.1	Introduction	81
5.2	Long-acting β_2 -agonists	82
5.3	Novel ultra-long-acting β_2 -agonists	86
5.4	Conclusion	95
	References	95
6	The safety of long-acting beta-agonists and the development of combination therapies for asthma and COPD	102
	<i>Victor E. Ortega and Eugene R. Bleeker</i>	
6.1	Introduction	102
6.2	Asthma-related mortality and beta-agonist exposure	103
6.3	Long-acting beta-agonists and increased asthma-related mortality	105
6.4	Safety and efficacy of LABA therapy in asthma: retrospective analyses	107

CONTENTS

vii

6.5	Efficacy of LABA therapy as a component of combination therapy with ICS for the management of asthma	110
6.6	Scientific basis of the beneficial and adverse effects of beta-agonist therapy: <i>in vitro</i> data and the beta-agonist paradox	113
6.7	Conclusions regarding the safety of LABA therapy as a component of combination therapy with ICS for the management of asthma	114
6.8	Beta-agonist therapy and adverse events in COPD	115
6.9	Safety and efficacy of LABA therapy in the management of COPD: the clinical evidence	116
6.10	Role of LABA therapy as a component of combination therapy with ICS for the management of COPD	117
6.11	Conclusions regarding the safety of LABA therapy as a component of combination therapy for the management of COPD	120
6.12	Pharmacogenetics of LABAs and combination therapy	120
6.13	Safety and efficacy of LABA therapy and the development of combination therapies for the management of asthma and COPD	126
6.14	Summary and future directions	127
	Acknowledgement	128
	References	128
7	Inhaled combination therapy with glucocorticoids and long-acting β_2-agonists in asthma and COPD, current and future perspectives	135
	<i>Jan Lötvall</i>	
7.1	Pharmacological management guidelines of asthma and COPD	135
7.2	Steroid treatment in asthma	136
7.3	Effects of adding LABA to inhaled glucocorticoids in asthma	137
7.4	Steroid treatment in COPD	140
7.5	Effects of LABAs in COPD	140
7.6	Combination inhalers versus two separate inhalers for inhaled GCS and LABAs	141
7.7	Regular treatment alone versus additional formoterol-containing combinations as reliever therapy	143
7.8	Currently available combination inhalers	145
7.9	Upcoming and alternative combinations of inhaled GCS and LABAs	146
7.10	Future of combined inhalation therapy in respiratory disease	148
	References	149
8	Novel anti-inflammatory treatments for asthma and COPD	154
	<i>Paul A. Kirkham, Gaetano Caramori, K. Fan Chung and Ian M. Adcock</i>	
8.1	Introduction	154
8.2	Current asthma and COPD therapies	158
8.3	The need for new therapies	160
8.4	Improving current therapies	162
8.5	Targeting chemokines and their receptors in asthma and COPD	166
8.6	Targeting T-cell-derived and proinflammatory cytokines in asthma and COPD	169

8.7	Targeting adhesion molecules in asthma and COPD	172
8.8	Growth factor blockers in asthma and COPD	173
8.9	Mucous cells, submucosal glands and mucus production in asthma and COPD	173
8.10	Infections in asthma and COPD	174
8.11	Intracellular signalling pathways	175
8.12	Inhibition of transcription factors in asthma and COPD	178
8.13	Antioxidants in asthma and COPD	181
8.14	Immunomodulation and anti-allergy treatments in asthma and COPD	182
8.15	Conclusions	185
	Acknowledgements	186
	References	186
9	Novel biologicals alone and in combination in asthma and allergy	203
	<i>Sharmilee M. Nyenhuis and William W. Busse</i>	
9.1	Introduction	203
9.2	Targets of therapy	204
9.3	Interleukin-4	204
9.4	Interleukin-5	207
9.5	Interleukin-13	211
9.6	Tumor necrosis factor- α	212
9.7	Immunoglobulin E	215
9.8	DNA vaccines	220
9.9	Future directions	222
9.10	Conclusion	224
	References	225
10	Anti-infective treatments in asthma and COPD	232
	<i>Jonathan D.R. Macintyre and Sebastian L. Johnston</i>	
10.1	Introduction	232
10.2	Current guidelines	234
10.3	Acute exacerbations of asthma	236
10.4	Increased susceptibility to infection in asthmatics	236
10.5	Role of atypical bacteria in asthma	237
10.6	Role of viruses in asthma exacerbations	244
10.7	Anti-infectives in COPD exacerbations	250
10.8	Use of antibiotics in stable COPD	256
10.9	Role of vaccination	257
10.10	Conclusion	259
	References	260
11	Long-acting muscarinic antagonists in asthma and COPD	268
	<i>M. Diane Loughheed, Josuel Ora and Denis E. O'Donnell</i>	
11.1	Introduction	268
11.2	Innervation of the airways	268

CONTENTS		ix
11.3	Cholinergic mechanisms in asthma and COPD	270
11.4	Role of long-acting anticholinergic bronchodilators in obstructive lung disease	271
11.5	Summary	287
	References	288
12	Phosphodiesterase inhibitors in obstructive lung disease	296
	<i>Jan Lötvall and Bo Lundbäck</i>	
12.1	Introduction	296
12.2	Phosphodiesterase enzymes	297
12.3	Different pharmacological agents blocking PDE4	298
12.4	Biological effects of PDE4 inhibition, preclinical information	300
12.5	Clinical effects of PDE4 inhibition in COPD	302
12.6	Effects of PDE4 inhibitors on systemic processes in COPD	304
12.7	Side effects of PDE4 inhibitors	304
12.8	PDE4 inhibitors in COPD management plans	305
12.9	Future prospects with PDE4 inhibitors in obstructive airways disease	305
12.10	Summary	306
	References	306
13	Biological therapies in development for COPD	311
	<i>J. Morjaria and R. Polosa</i>	
13.1	Introduction	311
13.2	Inflammatory cells involved in the pathogenesis of COPD	312
13.3	Cytokines and chemokines in COPD	315
13.4	Development of biological agents in COPD	320
13.5	Conclusions	323
	References	323
14	'Triple therapy' in the management of COPD: inhaled steroid, long-acting anticholinergic and long-acting β_2-agonist	333
	<i>Ronald Dahl</i>	
14.1	Introduction	333
14.2	Long-acting inhaled anticholinergic (LAMA) and β_2 -agonist (LABA) bronchodilators	333
14.3	Treatment strategies for COPD	334
14.4	Inhaled corticosteroids and COPD	334
14.5	Combination treatment with ICS, LAMA and LABA: 'triple therapy'	335
14.6	Extracted data from TORCH and UPLIFT studies	337
14.7	Conclusions	340
	References	341
	Index	343

P1: OTA/XYZ
JWST083-FM

P2: ABC
JWST083-Lötvall

September 22, 2011

12:46

Printer Name: Yet to Come